Clinical Trial Update: A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing upadacitinib to placebo in patients with active psoriatic arthritis who had an inadequate response to at least one biologic DMARD has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2022-01-25